Angiogenesis

Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM.

2-Furoyl-LIGRLO-amide TFA is a potent and selective proteinase-activated receptor 2 (PAR2) agonist with a pD2 value of 7.0.

Deoxyshikonin is a natural product isolated from Lithospermum erythrorhizon Sieb with antitumor activity.

Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.

BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay.

An inhibitor of HIF-1 signaling

Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor.

Orelabrutinib is an orally administered, potent, irreversible and highly selective BTK-inhibitor with an IC 50 value of 1.6nM.

Pazopanib-d6 is intended for use as an internal standard for the quantification of pazopanib by GC- or LC-MS.

Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS.

(±)11(12)-EET is a fully racemic version of the R/S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.

LYG-202 is a synthesized flavonoid with a piperazine substitution, exhibiting potent antitumor effects.

Spirolaxine is a long-chain phthalide produced by the fungus S.

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers.

Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina.

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers.

Oroxylin A is an active flavonoid with anti-inflammatory, anti-bacterial, anti-viral, and anti-cancer properties.

(±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases.

(±)16(17)-DiHDPA is produced from cytochrome P450 epoxygenase action on docosahexaenoic acid.

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively).

4-hydroxy Nebivolol is a major metabolite of nebivolol.

Axitinib sulfoxide is a major inactive metabolite of the tyrosine kinase inhibitor axitinib.

CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM.